|Last Price$21.07||Day Change (%)-0.52%|
|Open Price$21.07||Day Change ($)-0.11|
|Day Range21.07–21.07||52-Week Range19.92–24.75|
As of Mon 04/24/2017 | USD
Here's how much Mylan's U.S. EpiPen recall could cost it
UPDATE: Here's how much Mylan's U.S. EpiPen recall could cost it
Hagens Berman: EpiPen Purchasers Accuse Drug Maker Mylan of Fraud, RICO Enterprise in National Class-Action Lawsuit over EpiPen Pricing
UPDATE: Mylan's EpiPen recall likely to have low U.S. revenue impact: EvercoreISI analyst
Global Atopic Dermatitis Drugs Market 2017-2021 with LEO Pharma, Mylan , Valeant, Bayer HealthCare & Encore Dermatology Dominating - Research and Markets
Mylan stock slumps 1.3% after company says voluntary recall will include U.S. EpiPens
UPDATE: Mylan stock sinks 2% after FDA fails to approve its generic asthma medication
Global $228.8 Billion Generic Drugs Market 2017-2022 - Key Players are Freseunis, Hospira, Mylan , Novartis, Sandoz & Teva Pharmaceuticals - Research and Markets
Watson Pharmaceuticals WPI scored big Tuesday when the Food and Drug Administration approved the firm's generic fentanyl patch. We may modestly increase our fair value estimate for Watson and will maintain our fair value estimate for competitor Mylan Laboratories MYL . The pain patch is one of the ...
Mylan Laboratories MYL reported impressive second-quarter results Wednesday. However, most of the improvement was temporary and will not affect our fair value estimate. The quarter was only slightly better than we expected after excluding a one-time litigation payment and proceeds from a product ...